Ilika announces capital raising to advance battery technology

Ilika plc (AIM:IKA) announced a capital raise aiming to generate approximately £3.5 million through the issuance of 9,009,090 new ordinary shares at 33 pence per share, a 2.9% discount. The funds will support the commercial launch of Stereax technology and the development of Goliath technology, with the goal of securing commercial licensing agreements. Cavendish Capital Markets Limited is acting as the nominated adviser and sole bookrunner for the accelerated bookbuild placing, which is not conditional upon shareholder approval.

Analysis

Ilika plc (AIM:IKA), a UK-based firm specializing in solid-state battery technology, has announced a strategic capital raise targeting approximately £3.5 million. This will be primarily achieved through a placing of up to 9,009,090 new ordinary shares at 33 pence each, a price representing a 2.9% discount to the closing mid-market price on the day prior to the announcement. This new share issuance will account for roughly 5.4% of the company's existing issued ordinary share capital, leading to a degree of dilution for current investors. The net proceeds are specifically allocated, with up to £1.1 million designated for the commercial launch and scale-up of its small-format Stereax technology, and up to £2.4 million for the continued development of its large-format Goliath technology. A core objective for Ilika is to secure commercial licensing agreements for both product lines. The fundraising, which includes a retail offer via the Bookbuild platform and director subscriptions in addition to the placing, is managed by Cavendish Capital Markets Limited. Importantly, this capital raise is not conditional upon shareholder approval and is not underwritten, proceeding via an accelerated bookbuild. The neutral sentiment score of -0.1 for both the general market reaction and specifically for IKA suggests that the market views this move as a typical step for a development-stage technology company, balancing the need for growth capital against the dilutive effect of the share issue.

Key Decisions for Investors

• Investors should closely monitor Ilika's execution on the commercial launch of Stereax and the developmental milestones for Goliath, as the success of these initiatives is critical to validating the use of the newly raised capital.
• Existing shareholders need to evaluate the impact of the approximate 5.4% dilution resulting from the new share issuance against the strategic imperative of funding the company's growth and commercialization efforts, and may consider the terms of the retail offer.
• Potential investors should consider that while the funds are aimed at pivotal product advancements and commercialization, the investment carries risks inherent in technology development, including the timeline to achieve commercial licensing agreements and subsequent market adoption.